CHA News

CHA Comments on Proposed Payment Model to Lower Prescription Drug Costs

CHA has submitted comments to the Center for Medicare & Medicaid Innovation in response to its anticipated Accelerating Clinical Evidence (ACE) model.  

The ACE model would adjust Medicare Part B payment amounts for accelerated approval program drugs to give manufacturers an incentive to expedite and complete confirmatory clinical trials.  CMS did not include a timeline for when the model will begin.